Disseminated intravascular coagulation

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 695-705

  Levi, Marcel ^a,d   De Jonge, Evert ^b   Van Der Poll, Tom ^a,b   Ten Cate, Hugo ^a,c  

^a Department of Vascular Medicine ^*  (Netherlands)

^b Onze Lieve Vrouwe Gasthuis   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING INHIBITOR; CYTOKINE;

BLOOD CLOTTING; CONFERENCE PAPER; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; PATHOGENESIS; PLASMA TRANSFUSION; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

EID: 0032699060     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615899     Document Type: Conference Paper

References (81)

1. Marder VJ, Martin SE, Francis CW, Colman RW. Consumptive thrombohemorrhagic disorders. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: JB Lippincott Co; 1987:975-1015.
2. Williams EC, Mosher DF. Disseminated intravascular coagulation. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. Hematology. Basic principles and practice. New York: Churchill Livingstone; 1995:1758-1769.
3. Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. Br Med J. 1996;312:683-687.
4. Müller-Berghaus G, Madlener K, Blombäck M, ten Cate JW, eds. DIC. Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. New York: Elsevier Science Publishers; 1993.
5. Levi M, van der Poll T, ten Cate H, van Deventer SJH. The cytokine-mediated imbalance between coagulant and anti-coagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest. 1997;27:3-9.
6. Bick RL. Disseminated intravascular coagulation: a common complication of trauma and shock. In: Borris LC, Lassen MR, Bergqvist D, eds. The Traumatized Patient. City: Romer Grafik; 1992:33-53.
7. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost. 1996;75:224-228.
8. Roumen JMH, Hendriks T, van der Ven J, Nieuwenhuijzen GAP, Sauerwein RW, van der Meer JWWM, Goris RJA. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Ann Surg. 1993;6:769-776.
9. Contrino J, Hair G, Kreutzer D, Rickles FR. In situ detection of expression of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast tissue. Nature Med. 1996;2:209-215.
10. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94:1320-1327.
11. Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, Gordon SG, Barbui T. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 1998;92:143-151.
12. Albarracin NS, Haust MD. Intravascular coagulation in promyeolocytic leukemia: a case study including ultrastructure. Am J Clin Pathol. 1971;55:677-679.
13. Weiner CP. The obstetric patient and disseminated intravascular coagulation. Clin Perinatol. 1986;13:705-717.
14. Martin JN, Stedman CM. Imitators of preeclampsia and HELLP syndrome. Obstet Gynecol Clin North Am. 1991;18:181-198.
15. Gibney EJ, Bouchier-Hayes D. Coagulopathy and abdominal aortic aneurysm. Eur J Vasc Surg. 1990;4:557-562.
16. Szlachetka DM. Kasabach-Merrit syndrome: a case review. Neonat Network. 1998;17:7-15.
17. Ruggenenti P, Lutz J, Remuzzi G. Pathogenesis and treatment of thrombotic microangiopathy. Kidney Int. 1997;58:S97-S101.
18. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med. 1994;154:26-34.
19. Scherer RU, Spangenberg P. Procoagulant activity in patients with isolated head trauma. Crit Care Med. 1998;26:149-156.
20. Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, Gee T, Straus D, Gansbacher B, Filippa D, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood. 1992;79:1305-1310.
21. Aboulafia DM, Aboulafia ED. Aortic anurysma-induced disseminated intravascular coagulation. Ann Vasc Surg. 1996;10:396-405.
22. Coalson JJ. Pathology of sepsis, septic shock, and multiple organ failure. In: Perspective on Sepsis and Septic Shock. Fullerton, CA: Society of Critical Care Medicine; 1986:27-59.
23. Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91:2850-2860.
24. Kessler C, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacological dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs; substantial reduction in mortality and morbidity. Blood. 1997;89:4393-4401.
25. Fourrier F, Chopin C, Goudemand J, Hendryex S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101:816-823.
26. van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76:2520-2526.
27. Taylor FB Jr. Role of tissue factor in the coagulant and inflammatory response to LD100 E coli sepsis and in the early diagnosis of DIC in the baboon. In: Muller-Berghaus GM, Madlener K, Blomback M, ten Cate JW, eds. DIC. Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Amsterdam: Excerpta Medica; 1993:19-32.
28. van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990;322:1622-1627.
29. Pixley RA, de la Cadena R, Page J, Kaufman N, Wyshock EG, Chang A, Taylor FB Jr, Coman RW. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: in vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest. 1993;92:61-68.
30. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD. Inhibiton of endotoxin-induced activation of coagulation and fibrinolysis by pentoxiphylline or by a monoclonal anti-tissue factor antibody in a chimpanzee model. J Clin Invest. 1994;93:114-120.
31. Biemond BJ, Levi M, ten Cate H, Soule HR, Morris LD, Foster DL, Bogowitz CA, van der Poll T, Buller HR, ten Cate JW. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monclonal antibody to factor VII/VIIa. Thromb Haemost. 1995;73:223-230.
32. Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS. Lethal E coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991;33:127-134.
33. Wada H, Nakase T, Nakaya R, et al. Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation. Am J Hematol. 1996;52:165-170.
34. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infections related to unfavourable prognosis. Thromb Haemost. 1983;49:5-7.
35. Buller HR, ten Cate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med. 1989;87:44S-48S.
36. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol. 1988;8:5588-5592.
37. Taylor FB, Chang A Jr, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79:918-925.
38. Garcia de Frutos P, Alim RIM, Härdig Y, Zöller B, Dahlbäck B. Differential regulation of aa and bb chains of C4b-binding protein during acute phase response resulting in stable plasma levels of free anticoagulant protein S. Blood. 1994;84:815-822.
39. Taylor FB, Chang A, Ferrel G, Mather T, Catlett R, Blick K, Esmon CT. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78:357-363.
40. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991;78:387-393.
41. Suffredini AF, Harpel PC, Parillo JE. Promotion and subsequent inhibition of plasminogen activator after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989;320:1165-1172.
42. Biemond BJ, Levi M, ten Cate H, van der Poll T, Buller HR, Hack CE, ten Cate JW. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci. 1995;88:587-594.
43. Minnema MC, Pajkrt D, Wuillemin WA, Roem D, Bleeker WK, Levi M, van Devente SJ, Hack CE, ten Cate H. Activation of coagulation factor XI without detectable contact activation in experimental human endotoxemia. Blood. 1998;92:3294-3301.
44. Bouma BN, van der Borne PA, Meijers JCM. Factor XI and protection of the fibrin clot against lysis-a role for the intrinsic pathway of coagulation in fibrinolyis. Thromb Haemost. 1998;80:24-27.
45. Braat EAM, Levi M, Bos R, Haverkate F, de Maat MPM, Rijken DC. The occurrence of the inactivation of single-chain urokinase-type plasminogen activator by thrombin in vivo. J Lab Clin Med. In press.
46. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol. 1997;66:101-195.
47. Fischer E, Marano MA, van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock but fails to alter host-responses to sublethal endotoxemia. J Clin Invest. 1992;89:1551-1557.
48. 2, and to the activation of the complement, coagulation and fibrinolytic systems. Arch Surg. 1995;130:739-748.
49. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 1989;74:165-172.
50. van der Poll T, Levi M, van Deventer SJ, ten Cate H, Haagmans BL, Biemond BJ, Buller HR, Hack CE, ten Cate JW. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood. 1994;83:446-451.
51. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF). Circ Shock. 1990;30:279-292.
52. van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJ, Eerenberg AJ, de Groot ER, Jansen J, Gallati H, Buller HR, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med. 1994;179:1253-1259.
53. Stouthard J, Levi M, Hack CE, Veenhof CHN, Romijn JA, Sauerwein HP, van der Poll T. Interleukin 6 stimulates coagulation but not fibrinolysis in humans. Thromb Haemost. 1996,76:738-742.
54. Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Eschericia coli septic shock. J Clin Invest. 1993;91:2850-2855.
55. Mestries JC, Kruithof EK, Gascon MP, Herodin F, Agay D, Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Network. 1994;5:275-281.
56. Pajkrt D, van der Poll T, Levi M, Cutler DL, Affrime MB, van den Ende A, ten Cate JW, van Deventer SJ. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood. 1997;89:2701-2705.
57. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest. 1996;97:2440-2451.
58. Levi M, van der Poll T, ten Cate H, Kuipers B, Biemond BJ, Jansen HM, ten Cate JW. Differential effect of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Am J Respir Crit Care Med. 1998;158:92-98.
59. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemostas. 1996;22:69-88.
60. Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemostas. 1998;24:3-15.
61. Alving BM, Spivak JL, DeLoughery TG. Consultative hematology: hemostasis and transfusion issues in surgery and critical care medicine. In: McArthur JR, Schechter GP, Schrier SL, eds. Hematology. City: American Society of Hematology; 1998:320-341.
62. Gross SJ, Filston HC. Controlled study of treatment for disseminated intravascular coagulation in the neonate. J Pediatr. 1982;100:445-448.
63. du Toit HJ, Coetzee AR, Chalton DO. Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon. Crit Care Med. 1991;19:1195-1200.
64. Corrigan JJ Jr. Heparin therapy in bacterial septicemia. J Pediatr. 1977;91:695-700.
65. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood. 1982;60:284-287.
66. Goldhaber SZ. Venous thromboembolism in the intensive care unit: the last frontier. Chest. 1998;113:5-7.
67. Audibert G, Lambert H, Toulemonde F, Alexandre P, Laprevote-Heully MC, Bollaert PE, Bauer P, Larcan A. Utilisation d'une heparine de bas poids moleculaire, la CY 222, dans le traitement des coagulopathies de consommation. J Mal Vasc. 1987;12(Suppl):147-151.
68. Gillis S, Dann EJ, Eldor A. Low molecular weight heparin in the prophylaxis and treatment of disseminated intravascular coagulation in acute promyelocytic leukemia. Eur J Haematol. 1995;54:59-60.
69. Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)-a multi-center co-operative double-blind trial in comparison with heparin. Thromb Res. 1993;72:475-500.
70. Hermida J, Montes R, Paramo JA, Rocha E. Endotoxin-induced disseminated intravascular coagulation in rabbits: effect of recombinant hirudin on hemostatic parameters, fibrin deposits and mortality. J Lab Clin Med. 1998;131:77-83.
71. Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Matsuda T. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy. Blood Coagul Fibrinolysis. 1995;6:60-64.
72. Bergum P, Cruikshank A, Maki S, Ruf W, Vlasuk G. The potent, factor X(a)-dependent inhibition by rNAPc2 of factor VIIa/tissue factor involves the binding of its cofactor to a exosite on factor VII, followed by occupation of the active site. Blood. 1998;92(Suppl):2760a.
73. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIG: a randomized study. Thromb Res. 1985;39:81-89.
74. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular. Semin Thromb Hemostas. 1989;15:347-352.
75. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993;104:882-888.
76. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, Carugo D, Palareti G, Legnani C, Ridolfi L, Rossi R, D'Angelo A, Crippa L, Giudici D, Gallioli G, Wolfler A, Calori G. Antithrombin III replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998;24:336-342.
77. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U. Antithrombin III in patients with severe sepsis. A randomized placebo-controlled, double-blind multicenter trial plus meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;24:663-672.
78. Schuster HP, Matthias FR. Antithrombin III in severe sepsis. Presented at the 15th International Symposium on Intensive Care and Emergency Medicine; Month 1995; Brussels, Belgium.
79. Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B, Casey W. Use of protein C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet. 1997;350:1590-1593.
80. Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Intern Med. 1986;105:873-877.
81. Avvisati G, ten Cate JW, Buller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989;334:122-124.